Sublethal endotoxin administration evokes super-resistance to systemic hypoxia in rats

Journal of Trauma

Volumn 54, Issue 3, 2003, Pages 584-589

  Hiki, Naoki ^a   Mimura, Yoshikazu ^a   Hatao, Fumihiko ^a   Kojima, Junichi ^a   Ogawa, Toshihisa ^a   Tsuji, Eiichi ^a   Kaminishi, Michio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adaptation; Cross tolerance; Endotoxin tolerance; Hypoxia

Indexed keywords

ENDOTOXIN; INTERLEUKIN 6; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTATION; ALKALOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL BLOOD; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CONTROLLED STUDY; CROSS TOLERANCE; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; INFLAMMATION; LUNG FUNCTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; SURGICAL INJURY; VEIN CATHETERIZATION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANOXIA; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPINEPHRINE; INFLAMMATION; INTERLEUKIN-6; MALE; MYOCARDIAL ISCHEMIA; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037350602     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TA.0000060180.29719.57     Document Type: Article

References (37)

1. Clayer M, Bruckner J. Occult hypoxia after femoral neck fracture and elective hip surgery. Clin Orthop. 2000; 265-271.
2. Schlager A, Luger TJ. Oxygen application by a nasal probe prevents hypoxia but not rebreathing of carbon dioxide in patients undergoing eye surgery under local anaesthesia. Br J Ophthalmol. 2000; 84: 399-402.
3. Smith DC, Crul JF. Early postoperative hypoxia during transport. Br J Anaesth. 1988; 61: 625-627.
4. Dobkin AB. Postoperative hypoxia. N Engl J Med. 1969; 280: 1300.
5. Beeson PB. Tolerance to bacterial pyrogens. I. factors influencing its development. J ExP Med. 1947; 86: 29-38.
6. Mengozzi M, Ghezzi P. Cytokine down-regulation in endotoxin tolerance. Eur Cytokine Netw. 1993; 4: 89-98.
7. Meldrum DR, Sheridan BC, Cleveland JC Jr, Fullerton DA, Banerjee A, Harken AH. Neutrophils are required for endotoxin-induced myocardial cross- tolerance to ischemia-reperfusion injury. Arch Surg. 1996; 131: 1203-1208.
8. Arya G, Garcia VF. Hypoxia/reoxygenation affects endotoxin tolerance. J Surg Res. 1995; 59: 13-16.
9. Maulik N, Watanabe M, Engelman DT, Engelman RM, Das DK. Oxidative stress adaptation improves postischemic ventricular recovery. Molec Cell Biochem. 1995; 144: 67-74.
10. Maulik N, Watanabe M, Engelman D, et al. Myocardial adaptation to ischemia by oxidative stress induced by endotoxin. Am J Physiol. 1995; 269: C907-C916.
11. Brown JM, White CW, Terada LS, et al. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America. 1990;87:5026-5030.
12. Brown JM, Grosso MA, Terada LS, et al. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:2516-2520.
13. Neviere RR, Li FY, Singh T, Myers ML, Sibbald W. Endotoxin induces a dose-dependent myocardial cross-tolerance to ischemia-reperfusion injury. Crit Care Med. 2000; 28: 1439-1444.
14. Maulik N, Watanabe M, Engelman DT, Engelman RM, Das DK. Oxidative stress adaptation improves postischemic ventricular recovery. Mol Cell Biochem. 1995; 144: 67-74.
15. Heemann U, Szabo A, Hamar P, et al. Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury: possible connection to an interleukin-6- dependent pathway. Am J Pathol. 2000; 156: 287-293.
16. Meerson F, Pozharov V, Minyailenko T. Superresistance against hypoxia after preliminary adaptation to repeated stress. J Appl Physiol. 1994; 76: 1856-1861.
17. Miyano H, Kawada T, Sugimachi M, et al. Inhibition of NO synthesis does not potentiate dynamic cardiovascular response to sympathetic nerve activity. Am J Physiol. 1997; 273: H38-H43.
18. Gozal E, Simakajornboon N, Gozal D. NF-kappa B induction during in vivo hypoxia in dorsocaudal brain stem of rat: effect of MK-801 and L-NAME. J Appl Physiol. 1998; 85: 372-376.
19. Leeper-Woodford SK, Detmer K. Acute hypoxia increases alveolar macrophage tumor necrosis factor activity and alters NF-kappaB expression. Am J Physiol. 1999; 276: L909-L916.
20. Matsushita H, Kizaki M, Kobayashi H, Muto A, Ikeda Y. Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8. Br J Cancer. 1999; 79: 1325-1331.
21. Matsushita H, Morishita R, Nata T, et al. Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF- kappaB)-mediated bcl-2 suppression: in vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ Res. 2000; 86: 974-981.
22. Matsui H, Ihara Y, Fujio Y, et al. Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes. Cardiovasc Res. 1999; 42: 104-112.
23. Muraoka K, Shimizu K, Sun X, et al. Hypoxia, but not reoxygenation, induces interleukin 6 gene expression through NF-kappa B activation. Transplantation. 1997; 63: 466-470.
24. Schmedtje JFJ, Liu WL, Ji Y, Thompson TM, Runge MS. Evidence of hypoxia-inducible factor-1 in vascular endothelial and smooth muscle cells. Biochemical & Biophysical Research Communications. 1996; 220: 687-691.
25. Ertel W, Morrison MH, Ayala A, Chaudry IH. Hypoxemia in the absence of blood loss or significant hypotension causes inflammatory cytokine release. Am J Physiol. 1995; 269: R160-R166.
26. van der Poll T, Romijn JA, et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol. 1991; 261: E457-E465.
27. Stadelmann WK, Digenis AG, Tobin GR. Impediments to wound healing. Am J Surg. 1998; 176: 39S-47S.
28. Brimioulle S, Julien V, Gust R, Kozlowski JK, Naeije R, Schuster DP. Importance of hypoxic vasoconstriction in maintaining oxygenation during acute lung injury. Crit Care Med. 2002; 30: 874-880.
29. Wagner WW. Pulmonaly circulatory control through hypoxic vasoconstriction. Seminers in Respiratory Medicine. 1985; 7: 124-135.
30. Pruitt JH, Copeland EM III, Moldawer LL. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock [editorial]. Shock. 1995; 3: 235-251.
31. Kastenbauer S, Ziegler-Heitbrock HW. NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Infect Immun. 1999; 67: 1553-1559.
32. Blackwell TS, Blackwell TR, Christman JW. Impaired activation of nuclear factor-kappaB in endotoxin-tolerant rats is associated with down-regulation of chemokine gene expression and inhibition of neutrophilic lung inflammation. J Immunol. 1997; 158: 5934-5940.
33. Bohuslav J, Kravchenko VV, Parry GC, et al. Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest. 1998; 102: 1645-1652.
34. Wy CA, Goto M, Young RI, Myers TF, Muraskas J. Prophylactic Treatment of Endotoxic Shock with Monophosphoryl Lipid A in Newborn Rats. Biol Neonate. 2000; 77: 191-195.
35. Carpati CM, Astiz ME, Rackow EC, Kim JW, Kim YB, Weil MH. Monophosphoryl lipid A attenuates the effects of endotoxic shock in pigs. J Lab Clin Med. 1992; 119: 346-353.
36. Elliott GT. Monophosphoryl lipid A induces delayed preconditioning against cardiac ischemia-reperfusion injury. J Mol Cell Cardiol. 1998; 30: 3-17.
37. Astiz ME, Rackow EC, Still JG, et al. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med. 1995; 23: 9-17.